ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Medicinova Inc

Medicinova Inc (MNOV)

2.07
-0.05
(-2.36%)
終了 12月25日 6:00AM
2.07
0.00
( 0.00% )
プレマーケット: 8:02PM

個人投資家向けのプロ仕様のツール。

主要統計と詳細

通貨
2.07
買値
2.07
売値
2.40
出来高
-
0.00 日の範囲 0.00
1.12 52 週間の範囲 2.55
時価総額
前日終値
2.07
始値
-
時刻
最終取引時間
-
財務取引量
-
VWAP
-
平均取引量 (3 か月)
73,252
発行済株式数
49,046,246
配当利回り
-
PER
-11.84
1 株当たり利益 (EPS)
-0.17
歳入
1M
純利益
-8.57M

Medicinova Inc について

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's cu... MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases. It has the acquisition and development of the small molecule therapeutics segments. 詳細を表示

セクター
Pharmaceutical Preparations
業界
Pharmaceutical Preparations
ウェブサイト
本社
Wilmington, Delaware, USA
設立
-
Medicinova Inc is listed in the Pharmaceutical Preparations sector of the ナスダック市場 with ticker MNOV. The last closing price for Medicinova was US$2.07. Over the last year, Medicinova shares have traded in a share price range of US$ 1.12 to US$ 2.55.

Medicinova currently has 49,046,246 shares in issue. The market capitalisation of Medicinova is US$101.53 million. Medicinova has a price to earnings ratio (PE ratio) of -11.84.

MNOV 最新ニュース

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

LA JOLLA, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

LA JOLLA, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

LA JOLLA, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

LA JOLLA, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

LA JOLLA, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

LA JOLLA, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

LA JOLLA, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

LA JOLLA, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock...

期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.08-3.720930232562.152.23641.9482402.13450386CS
40.041.970443349752.032.481.9529162.22855615CS
120.084.020100502511.992.551.49732522.15256664CS
260.6343.751.442.551.12531811.96979322CS
520.6242.75862068971.452.551.12494681.7205933CS
156-0.72-25.80645161292.793.181.12518822.11306379CS
260-4.73-69.55882352946.813.251.122761946.38455996CS

MNOV - Frequently Asked Questions (FAQ)

What is the current Medicinova share price?
The current share price of Medicinova is US$ 2.07
How many Medicinova shares are in issue?
Medicinova has 49,046,246 shares in issue
What is the market cap of Medicinova?
The market capitalisation of Medicinova is USD 101.53M
What is the 1 year trading range for Medicinova share price?
Medicinova has traded in the range of US$ 1.12 to US$ 2.55 during the past year
What is the PE ratio of Medicinova?
The price to earnings ratio of Medicinova is -11.84
What is the cash to sales ratio of Medicinova?
The cash to sales ratio of Medicinova is 101.47
What is the reporting currency for Medicinova?
Medicinova reports financial results in USD
What is the latest annual turnover for Medicinova?
The latest annual turnover of Medicinova is USD 1M
What is the latest annual profit for Medicinova?
The latest annual profit of Medicinova is USD -8.57M
What is the registered address of Medicinova?
The registered address for Medicinova is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Medicinova website address?
The website address for Medicinova is www.medicinova.com
Which industry sector does Medicinova operate in?
Medicinova operates in the PHARMACEUTICAL PREPARATIONS sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
MGIHMillennium Group International Holdings Ltd
US$ 3.91
(155.56%)
13.19M
ZCARZoomcar Holdings Inc
US$ 3.23
(125.87%)
8.67M
ADDColor Star Technology Company Ltd
US$ 4.18
(93.52%)
5.17M
UPCUniverse Pharmaceuticals Inc
US$ 1.14
(79.87%)
4.38M
AIREreAlpha Tech Corporation
US$ 2.19
(59.85%)
13.07M
NEUPNeuphoria Therapeutics Inc
 4.13
(-37.71%)
60.08k
HOURHour Loop Inc
US$ 2.89
(-34.32%)
308.78k
DRCTDirect Digital Holdings Inc
US$ 2.45
(-33.96%)
331.09k
BAOSBaosheng Media Group Holdings Ltd
US$ 5.06
(-28.73%)
104.89k
SVRESaverOne 2014 Ltd
US$ 1.09
(-27.81%)
246.26k
LICNLichen China Limited
US$ 0.2751
(30.94%)
19.96M
MGIHMillennium Group International Holdings Ltd
US$ 3.91
(155.56%)
13.19M
AIREreAlpha Tech Corporation
US$ 2.19
(59.85%)
13.07M
ZCARZoomcar Holdings Inc
US$ 3.23
(125.87%)
8.67M
KWEKWESST Micro Systems Inc
US$ 0.6674
(19.86%)
6.39M

MNOV Discussion

投稿を表示

最近閲覧した銘柄